A
3.12
-0.33 (-9.57%)
| Penutupan Terdahulu | 3.45 |
| Buka | 3.49 |
| Jumlah Dagangan | 562,904 |
| Purata Dagangan (3B) | 1,675,640 |
| Modal Pasaran | 82,683,712 |
| Harga / Buku (P/B) | 6.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -2.24 |
| Nisbah Semasa (MRQ) | 10.68 |
| Aliran Tunai Operasi (OCF TTM) | -22.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.95 M |
| Pulangan Atas Aset (ROA TTM) | -91.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -280.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Annovis Bio, Inc. | Bercampur | Menurun |
AISkor Stockmoo
-1.9
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.88 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.69% |
| % Dimiliki oleh Institusi | 16.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merit Financial Group, Llc | 30 Sep 2025 | 81,316 |
| Greenwich Wealth Management Llc | 30 Sep 2025 | 47,400 |
| Wescott Financial Advisory Group, Llc | 30 Sep 2025 | 41,607 |
| Lokken Investment Group Llc | 30 Sep 2025 | 29,248 |
| Sterling Investment Advisors, Ltd. | 30 Sep 2025 | 23,416 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2025 | Pengumuman | Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients |
| 16 Dec 2025 | Pengumuman | Annovis to Host Corporate Update Webinar on January 28, 2026 |
| 03 Dec 2025 | Pengumuman | Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group |
| 24 Nov 2025 | Pengumuman | Annovis Announces Two Presentations at the CTAD 2025 Conference |
| 18 Nov 2025 | Pengumuman | Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study |
| 17 Nov 2025 | Pengumuman | Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients |
| 12 Nov 2025 | Pengumuman | Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results |
| 06 Nov 2025 | Pengumuman | Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |